ProMIS Neurosciences
$10.96
19
-$0.09-0.86% Today
Statistics
Day High
11.49
Day Low
10.88
52W High
28
52W Low
6.41
Volume
17,285
Avg. Volume
-
Mkt Cap
358.27M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
18MayExpected
Expected EPS
-1.06
Actual EPS
N/A
Financials
-Profit Margin
Profitable0Revenue
5.56MNet Income
Analyst Ratings
11.5Average Price Target
The highest estimate is 18.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow PMN. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap27.62B
Lilly(Eli) &
LLY
Mkt Cap862.01B
Pfizer
PFE
Mkt Cap149.77B
Merck
MRK
Mkt Cap277.02B
Abbvie
ABBV
Mkt Cap365.43B
Novartis
NVS
Mkt Cap279.67B
Acadia Pharmaceuticals
ACAD
Mkt Cap3.76B
Ionis Pharmaceuticals
IONS
Mkt Cap12.44B
About
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Show more...
CEO
Mr. Eugene W. Williams
Employees
7
Country
Canada
ISIN
CA74346M5054
Listings
0 Comments
Share your thoughts
FAQ
What is ProMIS Neurosciences stock price today?▼
The current price of PMN is $10.96 USD — it has decreased by -0.86% in the past 24 hours. Watch ProMIS Neurosciences stock price performance more closely on the chart.
What is ProMIS Neurosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ProMIS Neurosciences stocks are traded under the ticker PMN.
Is ProMIS Neurosciences stock price growing?▼
PMN stock has fallen by -1.7% compared to the previous week, the month change is a +0% rise, over the last year ProMIS Neurosciences has showed a -23.76% decrease.
What is ProMIS Neurosciences market cap?▼
Today ProMIS Neurosciences has the market capitalization of 358.27M
When is the next ProMIS Neurosciences earnings date?▼
ProMIS Neurosciences is going to release the next earnings report on May 18, 2026.
What were ProMIS Neurosciences earnings last quarter?▼
PMN earnings for the last quarter are -4.11 USD per share, whereas the estimation was -4.66 USD resulting in a +11.8% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ProMIS Neurosciences revenue for the last year?▼
ProMIS Neurosciences revenue for the last year amounts to 0 USD.
What is ProMIS Neurosciences net income for the last year?▼
PMN net income for the last year is 5.56M USD.
How many employees does ProMIS Neurosciences have?▼
As of May 06, 2026, the company has 7 employees.
In which sector is ProMIS Neurosciences located?▼
ProMIS Neurosciences operates in the Health & Wellness sector.
When did ProMIS Neurosciences complete a stock split?▼
The last stock split for ProMIS Neurosciences was on November 28, 2025 with a ratio of 1:25.
Where is ProMIS Neurosciences headquartered?▼
ProMIS Neurosciences is headquartered in Toronto, Canada.